GET A QUOTE

Varicella Zoster IgG ELISA Kit

  • Created on the 28 September, 2017.

BACKGROUND

Varicella-zoster virus (VZV) is an infectious disease which can cause chickenpox (varicella) during childhood and herpes zoster (singles) during adulthood. VZV is also referred to by many names, such as varicella virus, zoster virus, chickenpox virus and human herpesvirus type 3 (HHV-3). VZV predominately multiplies within the lungs and it can cause a number of different symptoms (pneumonia, bronchitis and encephalitis). Following the primary infection of chickenpox, the virus is found to go dormant in the nerve cells (examples of these include dorsal root ganglia, cranial nerve ganglia and autonomic ganglia). VZV is also very closely related to the herpes simplex viruses (HSV), displaying a high level of genome homology. The virons have a diameter of 180–200 nm, a lipid envelope enclosing the nucleocapsid and the DNA is a double stranded molecule which is 125,000 nucleotides long. Serological screen can be performed to test for IgG-class antibodies to VZV, this can help to identify non-immune individuals. Also, the identification of IgM-class antibodies to VZV can indicate a recent or acute infection but this needs to be correlated with clinical presentation.

INTENDED USE

Human varicella zoster-IgG ELISA kit is designed for analysing in-vitro quantitative concentrations of human IgG class antibodies against varicella zoster virus using serum or plasma. This assay has a minimum analytical sensitivity limit of 1.01 U/ml.

SENSITIVITY

The minimum detection sensitivity level of human varicella zoster IgG using this human varicella zoster-IgG ELISA kit was 1.01 U/ml. The dynamic assay range for this kit is 1.0 – 150.0 U/ml.

REFERENCES

  1. Reduced varicella-zoster-virus (VZV)-specific lymphocytes and IgG antibody avidity in solid organ transplant recipients. Vaccine. (2013) 31 (20): 2420-6. Prelog M., et al.
  2. Serological detection of specific IgG to varicella-zostervirus by novel ELISA based on viral glycoprotein antigen. Clin Lab. (2009) 55 (1-2): 1-7. Sauerbrei A. and Wutzler P.
  3. Varicella-zostervirus-specific, cell-mediated immunity with interferon-gamma release assay after vaccination of college students with no or intermediate IgG antibody response. J Med Virol. 2015 Feb;87(2):350-6. Terada K., et al.
  4. Serologic analysis of the IgG antibody response in children with varicella zoster virus wild-type infection and vaccination. Pediatr Infect Dis J. (2012) 31 (11): 1148-52. Jenke A.C., et al.
  5. Comparison of fifteen commercial assays for detecting Varicella Zostervirus IgG with reference to a time resolved fluorescence immunoassay (TRFIA) and the performance of two commercial assays for screening sera from immunocompromised individuals. J Virol Methods. (2009) 155 (2): 143-9. Chris Maple P.A., et al.

 

ADDITIONAL INFORMATION

  • Full Name: Varicella Zoster IgG ELISA Kit
  • Reactivity: Human
  • Sample Type: Plasma, Serum
  • Sensitivity: 1.01 U/ml

OTHER RELATED ELISA KITS

TESTIMONIALS arrow icon

Your secretory IgA ELISA kit gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA kit performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA kits from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA kits. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford